Author: venturaclinicaltrials (Page 2 of 2)
ULCERATIVE COLITIS? If you take Mesalamine for UC, but continue to struggle with your disease, learn more about this study evaluating a novel investigational UC food product.
-To pre-qualify for this study, you must be:
18 to 70 years of age and diagnosed with Ulcerative Colitis
Currently taking Mesalamine
Having an Ulcerative Colitis flare (increased UC symptoms)
-All study related visits, tests, and drugs will be provided to the participants at no cost. In addition, compensation for study related time and travel may be provided. Compensation can be up to $1,460 for qualifying patients.
To find out if you qualify for this study and compensation please fill out form and call 1 866 947 6815
Dr. Sabine Hazan
Dr. Sabine Hazan has over 23 years of experience in clinical trials and is the Founder and CEO at both Ventura Clinical Trials and Malibu Specialty Center. As Principal Investigator, Dr. Hazan personally oversees clinical trials for high profile studies on diseases such as Hepatitis C, Hypercholesterolemia, and Pancreatic Cancer. Her companies are leaders in Cardiovascular studies, Endocrine disorders, Infectious Diseases, Skin disorders and Gastrointestinal diseases and employ cutting edge technology and research practices to provide the best quality in drug therapy research.
The first woman ever accepted into the University of Florida as a Clinical Gastroenterology Fellow, Dr. Sabine Hazan is a pioneer in the medical field. Board certified in Gastroenterology, Hepatology, and Internal Medicine, Dr. Hazan has published articles in numerous prestigious medical journals, including the Journal of Duval County Medical Association and Gastroenterology, and won several awards, such as the Best Fellow Scientific Presentation and Dean’s Research Award awarded by University of Florida. In addition, Dr. Sabine Hazan is an acclaimed speaker and presented symposiums for influential medical organizations like the American Society for Gastrointestinal Endoscopy and Astra Merk, Inc.
Dr. Sabine Hazan is the former Chief of Medicine at Community Memorial Hospital and an active consultant for CRG. She currently retains medical licenses in three states (California, Florida, and New York).
Personal Philosophy
“I use logic when practicing and try to think outside the box. I always remind myself that much like every fingerprint is different, every patient’s symptom is different and one cannot practice like a robot. We are all humans attempting to stay a little bit longer on the planet. I never assume anything and never take anything lightly. I always try to be patient and listen and play detective with all the clues. Mostly, I realize that I am just a messenger and observe the miracles of healing that come from a higher power.
Every action leads to a reaction is pure scientific thinking but the reason behind the action is unknown. We, humans are only specks on this planet who must recognize the presence of a higher power. As hard as existence is for everyone, it is just that “an existence for a fraction of time” and as much as we come to doctors for answers we must realize that sometimes there are no answers or reason.”
Educational Background
1987 – 1992 DALHOUSIE UNIVERSITY, Nova Scotia, Canada
MEDICAL DIPLOMA (M.D) Awarded May 1992
1984 – 1987 CONCORDIA UNIVERSITY, Montreal, Canada
Bachelor of Sciences (BSc.) Biology Major, Physical Therapy and Minor Nutrition
1982 – 1984 CEGEP BREBEUF, Montreal, Canada
D.E.C. Specialty in Health, Pure & Applied Sciences
Publications
1) Be R, Hazan S, Gretz J, Buckley E, Kolts BE, McGee JB, Castell DO and SR Achem.Lower Esophageal Sphincter Relaxation time: Normal values and prevalence of abnormal values in Patients with Noncardiac Chest pain and /or dysphagia. Journal of Duval County Medical
Association. – 47;7;296. June 1996.
2) Hazan S, Buckley F, Castell DO and Achem SR. Octreotide Improves Sensory and Pain Thresholds in Patients with Noncardiac Chest Pain. Journal of the Duval County Medical Association. 47;7;291. June 1996.
3) Be R, Hazan S, Gretz J, Buckley E, Kolts BE, McGee JB, CasteLl DO an SR Achem. Lower Esophageal Sphincter Relaxation time: normal values and prevalence of abnormal values in Patients with Noncardiac Chest pain and/or Dysphagia. Gastroenterology. April 1996;110:A6
For Complete List of Publications Visit www.drsabinehazan.com/publications
Like many ULCERATIVE COLITIS (UC) patients, your doctor has prescribed mesalamine to treat your UC. While mesalamine can be effective against UC for some patients, other UC patients continue to struggle with symptoms of their disease
To pre-qualify for this study, you must be:
As a result, you may be considering additional options for
long-term treatment of your UC.
One option is this research study of an investigational drug that is taken along with your mesalamine prescription. In this study, local doctors want to evaluate an investigational drug called
LT-02 as an add-on treatment for UC.
The investigational drug, which is soy-based, is a delayed-release drug that is in the form of pellets and taken twice a day before a meal.
Doctors want to compare LT-02 with placebo, which looks like the investigational drug, but contains no active medication. The results of this study will provide more information about the investigational drug and whether it could one day be used as an add-on treatment with current UC medications.
Who is eligible to participate in this study?
• 18 to 70 years of age and diagnosed with ulcerative colitis
• Currently taking mesalamine
• Having an ulcerative colitis flare (increased UC symptoms)
All study-related visits, tests, and drugs will be provided to participants at no cost. In addition, compensation for study-related time and travel may be provided.
If you do not meet these eligibility criteria right now, but do so at a future date, please contact the study coordinator about your eligibility, using the telephone number on the back of this brochure.
What will happen during this study?
Before you can participate in the study, you must first be screened for eligibility. If you are eligible, and you agree to participate, you will be randomly assigned to one of two study groups.
One group will receive the investigational drug and one group will receive placebo. You have a 67% (2/3) chance of receiving the investigational drug and a 33% (1/3) chance of receiving placebo.
You, the study doctor, and the study staff will not know which study drug (investigational or placebo) you are receiving. This is to prevent any opinions about the study drugs from affecting the results of the study. However, in the event of an emergency, this information will be provided.
No matter which study drug you receive, you will take it in the morning and evening 30 to 60 minutes before a meal. You may mix your study drug with water, juice, milk, or yogurt. You will take your study drug twice a day for 12 weeks.
You total study participation will last approximately 20 weeks and includes 6 study clinic visits for treatment and
follow-up. Additionally, you will receive 1 phone call from the study staff. During your study clinic visits, study doctors and staff members will evaluate your health and progress through various tests and assessments. Some of these include, but are not limited to:
• Physical exams
• Vital signs measurements
• Blood and urine sample collections
• Endoscopy (looks at the lining of your colon)
• UC assessments
• Quality of life and work productivity questionnaires
• Reviews of medications you are currently taking
You will also be given an electronic diary and asked to record your daily UC symptoms and study drug dosing details. This diary must be completed every day in order for you to remain in the study.
If you complete the study, you may have the option to participate in an extension study in which all patients will receive the investigational drug.
What are the risks and benefits related to this study?
As with any medical research study, your study drug may not help your UC. The investigational medication has been studied before and most patients in those studies tolerated it well. However, it is possible that you could experience a side effect while in this study.
You will be closely monitored throughout this study. Researchers for this study are required to follow the study protocol, which explains all study procedures in detail. An independent review board responsible for patient safety has reviewed these procedures and approved this protocol.
What if I have questions?
The study staff is always available to answer any questions or concerns you may have about the study or the study drugs
To find out if you qualify for this study and compensation please fill out form and call 1800 920 0016
What is Fatty liver disease?
Fatty liver disease is very common in middle aged Americans, with the incidence increasing with the obesity epidemic. Major risk factors include obesity and type 2 diabetes, though it’s also associated with excessive alcohol consumption.
It usually causes no symptoms. When symptoms occur, they include fatigue, weight loss, and abdominal pain.
Treatment involves reducing the risk factors such as obesity through a diet and exercise program. It is generally a benign condition, but in a minority of patients, it can progress to liver failure (cirrhosis).
To find out if you qualify for this study and compensation please fill out form and call 1800 920 0016
What is Psoriasis
Psoriasis is a common skin condition that changes the life cycle of skin cells. Psoriasis causes cells to build up rapidly on the surface of the skin. The extra skin cells form thick, silvery scales and itchy, dry, red patches that are sometimes painful.
Psoriasis is a persistent, long-lasting (chronic) disease. There may be times when your psoriasis symptoms get better alternating with times your psoriasis worsens.
The primary goal of treatment is to stop the skin cells from growing so quickly. While there isn’t a cure, psoriasis treatments may offer significant relief. Lifestyle measures, such as using a nonprescription cortisone cream and exposing your skin to small amounts of natural sunlight, also may improve your psoriasis symptoms.
To find out if you qualify for this study and compensation please fill out form and call 1800 920 0016
What is Crohn’s disease?
Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people.
The inflammation caused by Crohn’s disease often spreads deep into the layers of affected bowel tissue. Crohn’s disease can be both painful and debilitating, and sometimes may lead to life-threatening complications.
While there’s no known cure for Crohn’s disease, therapies can greatly reduce its signs and symptoms and even bring about long-term remission. With treatment, many people with Crohn’s disease are able to function well
For further information on how we can help you, fill out the request form below.
Alon A. Steinberg, MD, FACC
Specialties
» Cardiovascular Consultations
» Cardiovascular Testing
» Nuclear Cardiology Certified
» Cardiovascular Computed Tomography (Cardiac CT) Certified
» Non-Interventional Cardiac Catheterization
Medical School
University of Texas Medical Branch
Internship
Jackson Memorial Hospital, University of Miami
Residency
Jackson Memorial Hospital, University of Miami
Fellowship
University of Florida Hospitals
Other
Cardiovascular MRI, Berlin Heart Institute
Board Certification
Cardiology
Nuclear Cardiology
Cardiac CT
Professional Associations
Fellow of American College of Cardiology
Society of Cardiovascular CT
Society of Cardiovascular MRI
California Medical Association
Ventura County Medical Association
Phi Beta Kappa
Expert Reviewer/consultant for the Medical Board of the State of California
Former Board Member of American Heart Association of Ventura County
For more information, http://www.expertcardiologist.com/
About Dr. Sabine Hazan
Dr. Sabine Hazan has over 22 years of experience in clinical trials and is the Founder and CEO at both Ventura Clinical Trials and Malibu Specialty Center. As Principal Investigator, Dr. Hazan personally oversees clinical trials for high profile studies on diseases such as Hepatitis C, Hypercholesterolemia, and Pancreatic Cancer. Her companies are leaders in Cardiovascular studies, Endocrine disorders, Infectious Diseases, Skin disorders and Gastrointestinal diseases and employ cutting edge technology and research practices to provide the best quality in drug therapy research.
The first woman ever accepted into the University of Florida as a Clinical Gastroenterology Fellow, Dr. Sabine Hazan is a pioneer in the medical field. Board certified in Gastroenterology, Hepatology, and Internal Medicine, Dr. Hazan has published articles in numerous prestigious medical journals, including theJournal of Duval County Medical Association and Gastroenterology, and won several awards, such as the Best Fellow Scientific Presentation and Dean’s Research Award awarded by University of Florida. In addition, Dr. Sabine Hazan is an acclaimed speaker and presented symposiums for influential medical organizations like the American Society for Gastrointestinal Endoscopy and Astra Merk, Inc.
Dr. Sabine Hazan is the former Chief of Medicine at Community Memorial Hospital and an active consultant for CRG. She currently retains medical licenses in three states (California, Florida, and New York).
[ninja_form id=1]
Personal Philosophy
“I use logic when practicing and try to think outside the box. I always remind myself that much like every fingerprint is different, every patient’s symptom is different and one cannot practice like a robot. We are all humans attempting to stay a little bit longer on the planet. I never assume anything and never take anything lightly. I always try to be patient and listen and play detective with all the clues. Mostly, I realize that I am just a messenger and observe the miracles of healing that come from a higher power.
Every action leads to a reaction is pure scientific thinking but the reason behind the action is unknown. We, humans are only specks on this planet who must recognize the presence of a higher power. As hard as existence is for everyone, it is just that “an existence for a fraction of time” and as much as we come to doctors for answers we must realize that sometimes there are no answers or reason.”
Educational Background
1987 – 1992 DALHOUSIE UNIVERSITY, Nova Scotia, Canada
MEDICAL DIPLOMA (M.D) Awarded May 1992
1984 – 1987 CONCORDIA UNIVERSITY, Montreal, Canada
Bachelor of Sciences (BSc.) Biology Major, Physical Therapy and Minor Nutrition
1982 – 1984 CEGEP BREBEUF, Montreal, Canada
D.E.C. Specialty in Health, Pure & Applied Sciences
Publications
1) Be R, Hazan S, Gretz J, Buckley E, Kolts BE, McGee JB, Castell DO and SR Achem.Lower Esophageal Sphincter Relaxation time: Normal values and prevalence of abnormal values in Patients with Noncardiac Chest pain and /or dysphagia. Journal of Duval County Medical
Association. – 47;7;296. June 1996.
2) Hazan S, Buckley F, Castell DO and Achem SR. Octreotide Improves Sensory and Pain Thresholds in Patients with Noncardiac Chest Pain. Journal of the Duval County Medical Association. 47;7;291. June 1996.
3) Be R, Hazan S, Gretz J, Buckley E, Kolts BE, McGee JB, CasteLl DO an SR Achem. Lower Esophageal Sphincter Relaxation time: normal values and prevalence of abnormal values in Patients with Noncardiac Chest pain and/or Dysphagia. Gastroenterology. April 1996;110:A6